EBR Systems Reports $169,704 Revenue in Q2 2025, Net Loss Increases

EBR Systems, Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $169,704, marking a significant increase from zero revenue in the same period last year. The company attributed this growth to the recent FDA approval of its WiSE CRT System, which allows for cardiac resynchronization therapy without the use of leads. Despite the revenue generation, EBR Systems recorded a net loss of $11,967,441 for the quarter, a slight increase from a loss of $11,494,688 in the prior year, primarily due to increased selling, general, and administrative expenses.

In terms of operational metrics, EBR Systems has made notable strides in its financial position. As of June 30, 2025, the company reported total assets of $114.9 million, up from $73.6 million at the end of 2024. This increase was driven by a substantial rise in cash and cash equivalents, which grew to $45 million from $6.9 million, largely due to successful capital raises. The company’s working capital also improved significantly, reaching $80.7 million, reflecting a strong liquidity position to support ongoing operations and strategic initiatives.

The company has expanded its workforce to support the commercialization of the WiSE CRT System, resulting in a 61% increase in selling, general, and administrative expenses to $5.3 million for the quarter. Research and development expenses, however, decreased by 20.4% to $5.9 million, indicating a strategic shift in resource allocation as the company transitions to commercialization. EBR Systems has also reported a total of 449.6 million shares outstanding as of June 30, 2025, following recent equity offerings that raised approximately $46.2 million.

Looking ahead, EBR Systems is focused on driving adoption of the WiSE CRT System in the U.S. and plans to expand into international markets once regulatory approvals are secured. The company has received preliminary approval for reimbursement schemes that are expected to enhance the financial viability of its product in the U.S. market. Management anticipates that existing cash reserves, along with projected revenues, will be sufficient to fund operations into the first quarter of 2027, although they acknowledge the ongoing need for additional capital to support growth and operational needs.

Overall, EBR Systems is navigating a critical phase of its business lifecycle, transitioning from development to commercialization while managing financial losses and operational expenses. The company’s ability to effectively market the WiSE CRT System and secure reimbursement will be pivotal in determining its future financial performance and market position.